Tempus AI, Inc. (TEM) Earnings Per Share (EPS): -1.72
Is Tempus AI, Inc.’s earnings per share (EPS) high or low?
Tempus AI, Inc.'s earnings per share (EPS) of -1.72 is 20% above its 5-year average of -2.16, near the high end of its 5-year range (-4.60–-1.41).
As of Friday, June 12, 2026. 42.76% above its 12-month average of -3.00.
TEM Earnings Per Share (EPS) Chart
TEM Average Earnings Per Share (EPS) Chart
TEM Current vs Average Earnings Per Share (EPS) Chart
TEM Earnings Per Share (EPS) Metrics
EARNINGS PER SHARE (EPS)
-1.72
EARNINGS PER SHARE (EPS) AVG TTM
-3.00
EARNINGS PER SHARE (EPS) AVG 3Y
-2.43
EARNINGS PER SHARE (EPS) AVG 5Y
-2.16
EARNINGS PER SHARE (EPS) AVG 10Y
-1.98
EARNINGS PER SHARE (EPS) AVG 15Y
-1.98
EARNINGS PER SHARE (EPS) AVG 20Y
-1.98
CURRENT VS TTM AVG
+42.76%
CURRENT VS 3Y AVG
+29.15%
CURRENT VS 5Y AVG
+20.31%
CURRENT VS 10Y AVG
+13.19%
CURRENT VS 15Y AVG
+13.19%
CURRENT VS 20Y AVG
+13.19%
TEM Competitors' Earnings Per Share (EPS)
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | -1.72 | -3.00 | -2.43 | -2.16 |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | -3.76 | -1.35 | 4.03 | 5.21 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 6.07 | -18.74 | -45.28 | 14.90 |
| Baxter International Inc. (BAX) | $10.58B | -2.10 | -1.51 | -0.65 | 0.36 |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | -0.09 | 0.57 | 0.18 | -0.06 |
| Align Technology, Inc. (ALGN) | $12.64B | 5.96 | 5.64 | 5.43 | 9.01 |
| Solventum Corporation (SOLV) | $13.72B | 8.17 | 5.85 | 6.82 | 7.06 |
| Hologic, Inc. (HOLX) | $16.97B | 2.40 | 2.92 | 3.22 | 4.07 |
| 23andMe Holding Co. (ME) | $15.31M | -9.05 | -19.23 | -15.56 | -14.25 |
| Moderna, Inc. (MRNA) | $19.70B | -8.15 | -8.27 | -1.90 | 3.46 |
EPS Comparison
Trailing EPS (TTM)
$-1.72
Forward EPS (Est.)
$-0.08
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
- Directly impacts stock valuation through P/E ratio
- Used to calculate dividend coverage and payout ratios
- Enables comparison across companies of different sizes
- Growth in EPS often correlates with stock price appreciation
Tempus AI, Inc. Earnings Per Share (EPS) Formula & Definition
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Earnings Per Share (EPS) FAQ
- What is the earnings per share (EPS) for Tempus AI, Inc. (TEM)?
- The earnings per share (EPS) for TEM stock is -1.72.
- Is Tempus AI, Inc.'s earnings per share (EPS) high or low?
- Tempus AI, Inc.'s earnings per share (EPS) of -1.72 is 20% above its 5-year average of -2.16, near the high end of its 5-year range (-4.60–-1.41).
- What is the TTM average earnings per share (EPS) for Tempus AI, Inc. (TEM)?
- The TTM average earnings per share (EPS) for TEM stock is -3.00.
- What is the 3Y average earnings per share (EPS) for Tempus AI, Inc. (TEM)?
- The 3Y average earnings per share (EPS) for TEM stock is -2.43.
- What is the 5Y average earnings per share (EPS) for Tempus AI, Inc. (TEM)?
- The 5Y average earnings per share (EPS) for TEM stock is -2.16.
- What is the 10Y average earnings per share (EPS) for Tempus AI, Inc. (TEM)?
- The 10Y average earnings per share (EPS) for TEM stock is -1.98.
- What is the 15Y average earnings per share (EPS) for Tempus AI, Inc. (TEM)?
- The 15Y average earnings per share (EPS) for TEM stock is -1.98.
- What is the 20Y average earnings per share (EPS) for Tempus AI, Inc. (TEM)?
- The 20Y average earnings per share (EPS) for TEM stock is -1.98.
Tempus AI, Inc. Earnings Per Share (EPS) History
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.41 |
| 2024-12-31 | -4.60 |
| 2023-12-31 | -1.73 |
| 2022-12-31 | -1.97 |
| 2021-12-31 | -1.75 |
| 2020-12-31 | -1.49 |
| 2019-12-31 | -0.92 |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky